Clinical trial / 2009
Oral ketogenic agent AC-1202 elevated serum ketones and improved ADAS-Cog scores compared with placebo in patients with mild to moderate Alzheimer's disease.
A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 152 participants diagnosed with mild to moderate Alzheimer's disease
- What was measured
- Mean change from baseline in ADAS-Cog and global scores in ADCS-CGIC
THE PAPER
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Nutr Metab (Lond), 2009.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.